Bioequivalence Study of Different Aprocitentan Tablet Formulations

Healthy Subjects Clinical Trial

Official title:

A Single-center, Open-label, Randomized, Two-way Crossover Phase 1 Study to Compare the Single-dose Pharmacokinetics of Different Tablet Formulations of Aprocitentan in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05196399
• Other study ID #: ID-080-110
• Secondary ID: 2021-005090-11
• Status: Completed
• Phase: Phase 1
• Start date: February 2, 2022
• Est. completion date: April 7, 2022

Study information

• Verified date: November 2022
• Source: Idorsia Pharmaceuticals Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose is to study the pharmacokinetics of aprocitentan (ACT-132577) using 2 different tablet formulations. The clinical pharmacology data will be used to determine bioequivalence of 2 different tablet formulations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: April 7, 2022
• Est. primary completion date: March 27, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Signed informed consent in a language understandable to the participant prior to any study-mandated procedure.
• Healthy male or female participant aged between 18 and 55 years (inclusive) at Screening.
• Body Mass Index of 18.0 to 30.0 kg/m2 (inclusive) at Screening.
• Systolic blood pressure (SBP) 100-140 mmHg, Diastolic blood pressure (DBP) 60-90 mmHg, and pulse rate 60-100 bpm (inclusive), measured on the dominant arm, after 5 min in the supine position at Screening and on Day 1 pre-dose of the first period.
• Woman of Childbearing Potential who has a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1 of the first period. She must agree to consistently and correctly use (from Screening, during the entire study, and for at least 30 days after the last study treatment administration) a highly effective method of contraception with a failure rate of less than 1% per year.
• Woman of non-childbearing potential, i.e., postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause; in addition, an FSH test must be performed at Screening to further support postmenopausal status), with previous bilateral salpingectomy, bilateral salpingo oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, uterine agenesis.

Exclusion Criteria:

• Pregnant or lactating woman.
• Previous administration of aprocitentan.
• Known hypersensitivity to endothelin receptor antagonists or to excipients used in any of the formulations.
• History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatments (appendectomy and herniotomy allowed, cholecystectomy not allowed).
• Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation of the study results.
• Clinically relevant findings on the physical examination at Screening and on Day -1 of the first period.
• Clinically relevant findings in clinical laboratory tests (hematology and clinical chemistry) at Screening and on Day -1 of the first period.
• Previous treatment with any prescribed medications (including vaccines) or over-the-counter medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 3 weeks or 5 terminal elimination half-lives (t½; whichever is longer) prior to first study treatment administration.
• Legal incapacity or limited legal capacity at Screening.
• Positive COVID-19 test, if performed (subject to current epidemiological regulations in the Czech Republic) during the screening period.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• Aprocitentan (Formulation A)
A single oral dose of 25 mg.
• Aprocitentan (Formulation B)
A single oral dose of 25 mg.

Locations

Country	Name	City	State
Czechia	CEPHA s.r.o.	Pilsen

Sponsors (1)

Lead Sponsor	Collaborator
Idorsia Pharmaceuticals Ltd.

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum plasma concentration (Cmax) of aprocitentan		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
Primary	The area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of aprocitentan		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
Primary	Area under the plasma concentration-time curve from zero to infinity (AUC0-inf) of aprocitentan		Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
Secondary	Treatment-emergent adverse events		From study treatment administration on Day 1 up to last assessment at End of Period (Day 10).